OncoBuddy

OncoBuddy, Your Companion in Cancer Care
Connect with patients on similar journeys and experts 24/7. Access curated cancer and health content.

[OncoBuddy @oncobuddy]

🧬 Biomarker Spotlight: ESR1
One mutation. One new treatment option.
The latest FDA approval of vepdegestrant reinforces why genomic profiling matters in ER+/HER2− metastatic breast cancer.
#ESR1 #PrecisionMedicine #NGS #4baseCare #OncoBuddy

[OncoBuddy @oncobuddy]

📈 From breast to bladder to rare cancers, May 2026 marks a turning point in precision oncology.
NGS-guided testing is the backbone of these breakthroughs.
@4basecare is proud to offer cutting-edge NGS solutions for clinicians & patients
#CancerCare #NGS #Oncobuddy

[OncoBuddy @oncobuddy]

🧬 Biomarker Spotlight: PTEN
Not all prostate cancers are the same.
Recent FDA approval of Capivasertib + Abiraterone for PTEN-deficient metastatic prostate cancer highlights the value of biomarker-guided treatment strategies. #PTEN #PrecisionOncology #NGS #4baseCare

[OncoBuddy @oncobuddy]

Datopotamab deruxtecan (Datroway) approved for unresectable/metastatic triple-negative breast cancer (TNBC). A new option for patients not eligible for PD-1/PD-L1 therapy.
Precision medicine powered by NGS is the future.
Learn more with @4basecare
#Oncobuddy #NGS #CancerCare

[OncoBuddy @oncobuddy]

🩸 Biomarker Spotlight: bTMB
Can a blood sample help guide cancer treatment?
bTMB is an emerging biomarker that may provide insights into immunotherapy response—highlighting the growing role of liquid biopsy in precision oncology.
#bTMB #Immunotherapy #NGS #4baseCare #OncoBuddy

[OncoBuddy @oncobuddy]

🧪 Bladder Cancer
Precision oncology milestone!
FDA approves atezolizumab for muscle-invasive bladder cancer patients with ctDNA molecular residual disease post-cystectomy.
NGS-driven ctDNA testing is transforming cancer management. Explore @4basecare’s NGS offerings
#Oncobuddy

[OncoBuddy @oncobuddy]

🧬 Biomarker Spotlight: EGFR
One biomarker, Multiple treatment possibilities.
Recent FDA advancements with Amivantamab + Lazertinib in EGFR-mutated NSCLC underscore how genomic insights can help guide precision treatment decisions.
#EGFR #LungCancer #NGS #4baseCare #OncoBuddy

[OncoBuddy @oncobuddy]

Breast Cancer Advances
🌸May 2026: FDA approves
datopotamab deruxtecan (Datroway) for metastatic TNBC
trastuzumab deruxtecan (Enhertu) for HER2+ early-stage breast cancer (neoadjuvant & adjuvant)
4basecare NGS tests ensures HER2 & PD-L1 status are accurately profiled.
#Oncobuddy

[OncoBuddy @oncobuddy]

🧬 Biomarker Spotlight: NRG1
Rare cancers deserve precise answers-The FDA approval of Zenocutuzumab for NRG1 fusion-positive cholangiocarcinoma underscores the impact of biomarker-driven therapies and importance of comprehensive genomic profiling. #NRG1 #NGS #PrecisionOncology

[OncoBuddy @oncobuddy]

🧬 Did You Know?

No two cancers are exactly alike.

Genomic profiling reveals the unique alterations driving each tumor—because the right treatment often starts with the right genomic insights.
#NGS #PrecisionOncology #OncoBuddy #4basecare

[OncoBuddy @oncobuddy]

From breast to bladder to rare cancers, May 2026 marks a turning point in precision oncology.
NGS-guided testing is the backbone of these breakthroughs.
@4basecare is proud to offer cutting-edge NGS solutions for clinicians & patients 👉 https://t.co/qTHS8sy7vO
#NGS #Oncobuddy

[OncoBuddy @oncobuddy]

From anal cancer to lung cancer, 13 new FDA immunotherapy approvals in 2025 mark a new era in oncology.
Checkpoint inhibitors + NGS biomarkers = smarter, earlier interventions.
@4basecare empowers clinicians with cutting-edge NGS tests 👉 https://t.co/qTHS8sy7vO
#Oncobuddy

[OncoBuddy @oncobuddy]

🚨 Big news in #TargetedTherapy!
In May 2026, Hernexeos® (zongertinib) became the first oral treatment for HER2‑mutant advanced lung cancer, showing a 75%+ response rate.
#OncoBuddy #CancerCare

[OncoBuddy @oncobuddy]

A new era in cancer care begins! With the launch of OncoBuddy app and 4basecare's targeted therapy, we made treatment more personalized, connected, and patient- focused. Together we're redefining hope with science #OncoBuddy #4basecare #Targetedtherapy

[OncoBuddy @oncobuddy]

A new era in cancer care begins! With the launch of OncoBuddy app and 4basecare's targeted therapy, we made treatment more personalized, connected, and patient- focused. Together we're redefining hope with science #OncoBuddy #4basecare #Targetedtherapy

[OncoBuddy @oncobuddy]

Decoding cancer, together. 💙 We're launching a special initiative to bring you the latest in Genomics & Cancer Care. Expect regular, expert-curated updates on breakthroughs from the OncoBuddy team.

Follow so you don't miss out!

#OncoBuddy #Genomics #CancerResearch

[OncoBuddy @oncobuddy]

Decoding cancer, together. 💙 We're launching a special initiative to bring you the latest in Genomics & Cancer Care. Expect regular, expert-curated updates on breakthroughs from the OncoBuddy team.

Follow so you don't miss out!

#OncoBuddy #Genomics #CancerResearch

[OncoBuddy @oncobuddy]

@higgsfield this site is really great in exploring. Must try

[Higgsfield AI 🧩 @higgsfield]

A Cannes-winning director shot a 22-min epic action-adventure horror AI film.

Made SOLO in just 1 week in Higgsfield Cinema Studio.

[OncoBuddy @oncobuddy]

What is OncoBuddy? | OncoBuddy is a digital healthcare platform

#oncology #oncobuddy #app #cancercareapp #4basecare #playstore #android